1,4-丁二醇二丙酸酯 | 1572-92-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1,4-丁二醇二丙酸酯
• 英文名称: 1,4-butanediol dipropionate
• 英文别名: 1,4-Butanediol, dipropionate；4-propanoyloxybutyl propanoate
• CAS: 1572-92-5
• 化学式: C₁₀H₁₈O₄
• 分子量: 202.251
• InChiKey: ADGOOVVFTLKVKH-UHFFFAOYSA-N

物化性质

• 沸点：
  92-93 °C(Press: 3 Torr)
• 密度：
  1.008±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  Butin-(2)-diol-(1,4)-bis-propionsaeureester 在 钯 氢气 作用下， 生成 1,4-丁二醇二丙酸酯
  参考文献：
  名称：

  Mikadze,Sh.G., Journal of Organic Chemistry USSR (English Translation), 1965, vol. 1, p. 462 - 466

  摘要：

  DOI：

文献信息

• Esterification of carboxylic acids with alkyl halides using imidazolium based dicationic ionic liquids containing bis-trifluoromethane sulfonimide anions at room temperature
  作者：Arvind H. Jadhav、Kyuyoung Lee、Sangho Koo、Jeong Gil Seo

  DOI：10.1039/c5ra00802f

  日期：——

  Task-specific RTILs of symmetrical N-methylimidazolium rings linked to an oligo (ethylene glycol) chain (cationic part) and bis-trifluoromethane sulfonimide (anionic part) were synthesized, and the physicochemical properties with catalytic activity were determined.

  将对称的N-甲基咪唑环与寡聚（乙二醇）链（阳离子部分）和双三氟甲磺酰亚胺（阴离子部分）相连的特定任务离子液体（Task-specific RTILs）合成，并确定其物理化学性质和催化活性。
• 1,4-丁二醇及其二羧酸酯的制备方法
  申请人：中国科学技术大学

  公开号：CN110218152B

  公开（公告）日：2021-08-13

  本发明涉及1,4‑丁二醇及其二羧酸酯的制备方法。具体地，1,4‑丁二醇及其二羧酸酯的制备方法包括以下步骤：将糠酸类化合物、三氟甲磺酸盐、加氢催化剂在羧酸溶剂中进行加氢脱羰酯化开环得到1,4‑丁二醇二羧酸酯。该方法具有工艺简单、易纯化、产率高、绿色安全等特点，适合大规模工业化生产。
• PROCESS FOR PREPARING 1,4-BUTANDIOL MONITRATE
  申请人：Hack Achim

  公开号：US20100137599A1

  公开（公告）日：2010-06-03

  The present invention relates to a process for the preparation of 1,4-butanediol mononitrate as intermediate for large scale preparation of high purity nitrooxybutyl ester of pharmaceutically active compounds.

  本发明涉及一种制备1,4-丁二醇单硝酸酯的方法，作为制备高纯度药用活性化合物硝氧基丁酯的中间体的大规模制备。
• Methods and dosage forms for controlled delivery of paliperidone and risperidone
  申请人：Yam V. Nyomi

  公开号：US20050232995A1

  公开（公告）日：2005-10-20

  Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

  本发明提供了用于提供相对升高的帕利哌酮或利培酮释放速率的剂型和方法。这种持续释放的剂型在每天一次的给药时提供治疗有效的平均稳态血浆帕利哌酮或利培酮浓度。这种一天一次的给药方案只会在每24小时内发生一次峰值血浆帕利哌酮或利培酮浓度。此外，峰值血浆帕利哌酮或利培酮浓度发生在给药后的较晚时间，并且比即时释放剂型的峰值血浆帕利哌酮或利培酮浓度具有较小的幅度。
• [EN] METHODS AND DOSAGE FORMS FOR CONTROLLED DELIVERY OF PALIPERIDONE<br/>[FR] TECHNIQUES ET FORMES DE DOSE D'APPORT COMMANDE DE PALIPERIDONE
  申请人：ALZA CORP

  公开号：WO2004010981A1

  公开（公告）日：2004-02-05

  Dosage forms and methods for providing a substantially ascending rate of release of paliperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone concentration that occurs following administration of paliperidone in an immediate-release dosage form.

  提供了用于提供相对上升速率的帕利哌酮释放的剂型和方法。持续释放的剂型在每天一次给药时提供治疗有效的平均稳态血浆帕利哌酮浓度。这种一天一次的给药方案导致每24小时期间仅出现一次峰值血浆帕利哌酮浓度。此外，峰值血浆帕利哌酮浓度发生在剂量给药后的较晚时间，并且比使用即时释放剂型的帕利哌酮给药后发生的峰值血浆帕利哌酮浓度小。

表征谱图